Search research articles
Contact Us
Filters
Showing results (481-490 of 499) with videos related to
Page
of 50
Sort By:
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
May 21, 2023
Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials
Quisette P Janssen, Rutger Quispel, Marc G Besselink, et al.
Therapeutic Advances in Medical Oncology
|
August 23, 2021
Circulating <i>TP53</i> mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX
Fleur van der Sijde, Zakia Azmani, Marc G Besselink, et al.
International Journal of Cancer
|
December 22, 2021
Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
Evelien J M de Jong, Quisette P Janssen, Tessa F A Simons, et al.
Plos One
|
January 25, 2023
Targeted next-generation sequencing has incremental value in the diagnostic work-up of patients with suspect pancreatic masses; a multi-center prospective cross sectional study
Friso B Achterberg, Babs G Sibinga Mulder, Quisette P Janssen, et al.
Vox Sanguinis
|
March 25, 2025
Clinical evaluation of red cell concentrates in non-DEHP plasticized containers compared with standard DEHP plasticized containers: A quasi-randomized observational multicentre study
Christie Vermeulen, Nan van Geloven, Bart Mertens, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
January 29, 2016
Cardiovascular malformations caused by NOTCH1 mutations do not keep left: data on 428 probands with left-sided CHD and their families
Wilhelmina S Kerstjens-Frederikse, Ingrid M B H van de Laar, Yvonne J Vos, et al.
BMC Cancer
|
March 24, 2021
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Q P Janssen, J L van Dam, B A Bonsing, et al.
Annals of Surgery
|
February 12, 2026
Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial
Ingmar F Rompen, Esther N Dekker, Thomas F Stoop, et al.
Annals of Surgical Oncology
|
December 20, 2022
Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study
Eran van Veldhuisen, Sjors Klompmaker, Quisette P Janssen, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
August 7, 2023
Diagnostic accuracy of endoscopic ultrasonography-guided tissue acquisition prior to resection of pancreatic carcinoma: a nationwide analysis
Rutger Quispel, Hannah M Schutz, Augustinus W P Keultjes, et al.
Page
of 50
Search research articles
Search
Showing results (481-490 of 499) with videos related to
Sort By:
Page
of 50
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
May 21, 2023
Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials
Quisette P Janssen, Rutger Quispel, Marc G Besselink, et al.
Therapeutic Advances in Medical Oncology
|
August 23, 2021
Circulating <i>TP53</i> mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX
Fleur van der Sijde, Zakia Azmani, Marc G Besselink, et al.
International Journal of Cancer
|
December 22, 2021
Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
Evelien J M de Jong, Quisette P Janssen, Tessa F A Simons, et al.
Plos One
|
January 25, 2023
Targeted next-generation sequencing has incremental value in the diagnostic work-up of patients with suspect pancreatic masses; a multi-center prospective cross sectional study
Friso B Achterberg, Babs G Sibinga Mulder, Quisette P Janssen, et al.
Vox Sanguinis
|
March 25, 2025
Clinical evaluation of red cell concentrates in non-DEHP plasticized containers compared with standard DEHP plasticized containers: A quasi-randomized observational multicentre study
Christie Vermeulen, Nan van Geloven, Bart Mertens, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
January 29, 2016
Cardiovascular malformations caused by NOTCH1 mutations do not keep left: data on 428 probands with left-sided CHD and their families
Wilhelmina S Kerstjens-Frederikse, Ingrid M B H van de Laar, Yvonne J Vos, et al.
BMC Cancer
|
March 24, 2021
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Q P Janssen, J L van Dam, B A Bonsing, et al.
Annals of Surgery
|
February 12, 2026
Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial
Ingmar F Rompen, Esther N Dekker, Thomas F Stoop, et al.
Annals of Surgical Oncology
|
December 20, 2022
Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study
Eran van Veldhuisen, Sjors Klompmaker, Quisette P Janssen, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
August 7, 2023
Diagnostic accuracy of endoscopic ultrasonography-guided tissue acquisition prior to resection of pancreatic carcinoma: a nationwide analysis
Rutger Quispel, Hannah M Schutz, Augustinus W P Keultjes, et al.
Page
of 50